Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 34 for:    shield II
Previous Study | Return to List | Next Study

Supporting Patients Undergoing HIgh-Risk PCI Using a High-Flow PErcutaneous Left Ventricular Support Device (SHIELD II) (SHIELD II)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02468778
Recruitment Status : Recruiting
First Posted : June 11, 2015
Last Update Posted : June 19, 2019
Sponsor:
Information provided by (Responsible Party):
Abbott Medical Devices

Brief Summary:
The HeartMate PHP System is a temporary (<6 hours) ventricular assist device indicated for use during high-risk percutaneous coronary interventions (PCI) performed electively or urgently in hemodynamically stable patients with severe coronary artery disease, when a heart team, including a cardiac surgeon, has determined high-risk PCI is the appropriate therapeutic option. Use of the HeartMate PHP Systems in these patients may prevent hemodynamic instability, which can result from repeat episodes of reversible myocardial ischemia that occur during planned temporary coronary occlusions and may reduce peri-and post-procedural adverse events

Condition or disease Intervention/treatment Phase
Coronary Artery Disease Device: HeartMate PHP Device: Any Abiomed Impella® device approved for use in high-risk PCI Not Applicable

Detailed Description:

Prospective, randomized, multi-center, open-label trial of the HeartMate PHP at up to 120 sites in the US and Europe. Control device will be any Abiomed Impella device approved for use in high-risk PCI.

This clinical investigation is divided into two phases, a feasibility phase and a pivotal phase.

  • Feasibility Phase: Includes 75 roll-in and 120 randomized subjects registered under the CIP versions 1-4 at 48 sites in the United States (U.S.) prior to January 30, 2017
  • Pivotal Phase: Includes subjects to be registered under the current or later version of the CIP at up to 120 sites in the U.S. and Europe

Non-randomized Roll-in Cohort: Up to 480 subjects with the HeartMate PHP; each operator must treat a minimum of 1 and up to 2 subjects with the HeartMate PHP first before becoming qualified to randomize subjects

Randomized Cohort: A minimum of 473 and a maximum of 716 subjects will be randomized in a 2:1 ratio to the HeartMate PHP and Impella.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 716 participants
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Supporting Patients Undergoing HIgh-Risk PCI Using a High-Flow PErcutaneous Left Ventricular Support Device (SHIELD II)
Actual Study Start Date : August 2015
Estimated Primary Completion Date : December 2020
Estimated Study Completion Date : December 2020

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: HeartMate PHP
The HeartMate PHP System is a temporary (<6 hours) ventricular assist device indicated for use during high-risk percutaneous coronary interventions (PCI) performed electively or urgently in hemodynamically stable patients with severe coronary artery disease, when a heart team, including a cardiac surgeon, has determined high-risk PCI is the appropriate therapeutic option. Use of the HeartMate PHP Systems in these patients may prevent hemodynamic instability, which can result from repeat episodes of reversible myocardial ischemia that occur during planned temporary coronary occlusions and may reduce peri-and post-procedural adverse events
Device: HeartMate PHP
The HeartMate PHP System is a temporary (<6 hours) ventricular assist device indicated for use during high-risk percutaneous coronary interventions (PCI) performed electively or urgently in hemodynamically stable patients with severe coronary artery disease, when a heart team, including a cardiac surgeon, has determined high-risk PCI is the appropriate therapeutic option. Use of the HeartMate PHP Systems in these patients may prevent hemodynamic instability, which can result from repeat episodes of reversible myocardial ischemia that occur during planned temporary coronary occlusions and may reduce peri-and post-procedural adverse events

Active Comparator: Any Abiomed Impella® device approved for use in high-risk PCI
Any Abiomed Impella® Device approved for use in high-risk PCI
Device: Any Abiomed Impella® device approved for use in high-risk PCI
Any Abiomed Impella® device approved for use in high-risk PCI




Primary Outcome Measures :
  1. Rate of participants with cardiovascular death, myocardial infarction, stroke, any repeat revascularization, bleeding (BARC 3 or 5), severe hypotension, or increase in aortic insufficiency from baseline to 90 days. [ Time Frame: 90 Days ]

    The primary endpoint is a composite endpoint. Rate of participants having any of below mentioned events will be recorded.

    • Cardiovascular death
    • Myocardial infarction
    • Stroke
    • Any repeat revascularization (PCI or CABG)
    • Bleeding (BARC 3 or 5)
    • Severe hypotension
    • Increase in aortic insufficiency from baseline to 90 days

    Note: Individual events will be recorded as separate endpoint under secondary outcome measures (as mentioned below).



Secondary Outcome Measures :
  1. Rate of participants with cardiovascular death [ Time Frame: 90 Days ]
    Cardiovascular death includes sudden cardiac death, death due to acute myocardial infarction, death due to heart failure or cardiogenic shock, death due to stroke, death due to other cardiovascular causes, and death due to bleeding.

  2. Rate of participants with myocardial Infarction [ Time Frame: 90 Days ]
    • Periprocedural MI (≤ 48 hours post PCI)
    • Spontaneous MI > 48 hours post PCI

  3. Rate of participants with stroke [ Time Frame: 90 Days ]
    Cerebral infarction occurring within 90 days after device use as measured by clinical assessment and/or diagnostic imaging.

  4. Rate of participants with any repeat revascularization (PCI or CABG) [ Time Frame: 90 Days ]
    Additional PCI or CABG surgery occurring within 90 days after device use.

  5. Rate of participants with bleeding (BARC category 3 or 5) [ Time Frame: 90 Days ]
    Major bleeding (BARC category 3 or 5) occurring within 90 days after device use.

  6. Rate of participants with severe hypotension [ Time Frame: 90 Days ]
    Systolic blood pressure or augmented diastolic pressure (whichever is greater) <90 mmHg while on device support requiring (1) more than one administration of OR (2) continuous infusion of inotropic/pressor medications to restore hemodynamics.

  7. Rate of participants with increase in aortic insufficiency from baseline to 90 days [ Time Frame: 90 Days ]
    Aortic insufficiency will be assessed by echocardiogram (done by the core lab), looking at the increase in aortic regurgitation from baseline.

  8. Rate of participants with all-cause death [ Time Frame: 90 Days ]
    Death due to any cause occurring within 90 days of device use

  9. Hemodynamic measure: Maximal change in cardiac power output (CPO) from pre-PCI while on device support [ Time Frame: Intraprocedural ]
    CPO as calculated from mean arterial pressure and cardiac output

  10. Hemodynamic measure: Maximal change in central venous pressure (CVP) from pre-PCI while on device support [ Time Frame: Intraprocedural ]
    CVP as measured by direct right heart catheterization

  11. Hemodynamic measure: Maximal change in mean arterial pressure (MAP) from pre-PCI while on device support [ Time Frame: Intraprocedural ]
    MAP as measured by direct right heart catheterization

  12. Hemodynamic measure: Maximal change in pulmonary artery pressure (PAP) from pre-PCI while on device support [ Time Frame: Intraprocedural ]
    PAP as measured by direct right heart catheterization

  13. Hemodynamic measure: Maximal change in pulmonary capillary wedge pressure (PCWP) from pre-PCI while on device support [ Time Frame: Intraprocedural ]
    PCWP as measured by direct right heart catheterization

  14. Hemodynamic measure: Maximal change in cardiac output (CO) from pre-PCI while on device support [ Time Frame: Intraprocedural ]
    CO as measured by direct right heart catheterization

  15. Hemodynamic measure: Maximal change in cardiac index (CI) from pre-PCI while on device support [ Time Frame: Intraprocedural ]
    CI as measured by direct right heart catheterization

  16. Rate of participants with device-related access site complication requiring intervention or device-related limb ischemia [ Time Frame: 90 Days ]
    Major and minor vascular complications, including those due to percutaneous closure device failure occurring within 90 days of device use

  17. Rate of participants with surgical intervention due to device complication or malfunction [ Time Frame: 90 Days ]
    Any device complication or malfunction requiring surgical intervention for resolution within 90 days of device use

  18. Duration of hospital stay [ Time Frame: Hospital Discharge ]
    Number of hospital days associated within the initial study hospitalization

  19. Intensive care unit (ICU) days [ Time Frame: Hospital Discharge ]
    Number of ICU days associated within the initial study hospitalization

  20. Rate of participants with increase in aortic insufficiency from baseline to post-procedure and/or from baseline to discharge [ Time Frame: At the time of post-procedure (within 48 hours post device removal) and again at the time of hospital discharge (typically within one week after the procedure) ]
    Aortic insufficiency will be assessed by echocardiogram (done by the core lab), looking at the increase in aortic regurgitation from baseline.

  21. Change in lactate dehydrogenase (LDH) from baseline to discharge [ Time Frame: At the time of hospital discharge (typically within one week after the procedure) ]
  22. Change in Plasma-free hemoglobin (PfHgb) from baseline to discharge [ Time Frame: At the time of hospital discharge (typically within one week after the procedure) ]
  23. Technical success (at exit from catheterization lab) [ Time Frame: At the time of procedure completion (typically within 6 hours after the study device is inserted) ]

    - Alive, with:

    1. Successful access, delivery, function and retrieval of the device, and
    2. Deployment and correct positioning of the single intended device, and
    3. No need for additional unplanned or emergency surgery or re-intervention related to the device or access procedure

  24. Device success (hospital discharge) [ Time Frame: At the time of hospital discharge (typically within one week after the procedure) ]

    - Alive and stroke free with:

    1. No peri-procedural MI or post-procedural spontaneous MI
    2. No additional interventional or surgical procedures related to device access (e.g., treatment of limb ischemia, etc.) or recurrent/ongoing myocardial ischemia (i.e., additional PCI or CABG after exit from catheterization lab)
    3. Intended performance of the device:

      1. No severe hypotension, defined as: SBP or augmented diastolic pressure (whichever is greater) < 90 mmHg while on device support requiring (1) more than one administration of OR (2) continuous infusion of inotropic/pressor medications to restore hemodynamics
      2. Complete revascularization of all ischemia-producing lesions achieved as planned (i.e., complete planned revascularization achieved)
      3. No structural cardiac device complications

  25. Rate of participants with re-hospitalizations, re-interventions, or surgery for the underlying condition (e.g. ischemic coronary artery disease) [ Time Frame: 90 days ]
  26. Change in quality of life questionnaires from baseline to 90 days - EQ-5D-5L [ Time Frame: 90 days ]

    The EQ-5D-5L consists of scores from 2 methods: the descriptive system and the visual analogue scale (VAS). Questionnaire in the the descriptive system covers the following dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. The VAS records the respondents' self-rated heath on a 20-cm vertical, visual analogue scale with endpoints labelled "the best health you can imagine" and "the worst health you can imagine."

    The descriptive system will have a summarized index value, ranging from 0 to 1, and the VAS will have a score ranging from 0 to 100. For each score, the higher the score, the better. The more positive change from baseline, the better the treatment effect.


  27. Change in quality of life questionnaires from baseline to 90 days - Seattle Angina Questionnaire (SAQ) [ Time Frame: 90 days ]

    There are 5 summary scores within the SAQ, which cover the 5 domains as follows.

    1. Physical limitation
    2. Angina stability
    3. Angina frequency
    4. Treatment satisfaction
    5. Quality of life

    The range of the score of SAQ will be 0-100 for each of the 5 domains. The higher the score, the better. The more positive change from baseline, the better the treatment effect.




Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 100 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • At least 18 years of age
  • Patient is undergoing elective or urgent high risk PCI procedure and is hemodynamically stable
  • Patient is indicated for a revascularization of at least one de novo or restenotic lesion in a native coronary vessel or bypass graft
  • A heart team, including a cardiac surgeon, has determined high risk PCI is an acceptable therapeutic option
  • Written, signed, and dated informed consent

Imaging Inclusion Criteria:

• The presence of complex coronary artery disease (CAD) makes hemodynamic instability resulting from repeat episodes of reversible myocardial ischemia during PCI likely. Complex CAD is defined as an ejection fraction of <50% AND at least one of the following:

  • intervention of the last patent coronary conduit, OR
  • intervention of an unprotected left main artery, OR
  • intervention on patient presenting with triple vessel disease defined as at least one significant stenosis (at least 50% diameter stenosis on visual assessment) in all three major epicardial territories

Exclusion Criteria:

  • Emergency PCI
  • Any prior coronary revascularization within the last 6 months
  • Hemodynamically unstable MI with elevated cardiac biomarker (creatinine kinase-MB (CK-MB) or troponin >1X upper limit of normal (ULN)) and no evidence of at least 1 consecutive CKMB or troponin value trending downward from previous value (at least 4 hours apart) OR ST Elevation MI (STEMI) within 72 hours prior to the index procedure regardless of the level of cardiac biomarker
  • Cardiac arrest within 24 hours of procedure requiring cardiopulmonary resuscitation (CPR) or defibrillation
  • Hemodynamic support with the HeartMate PHP post-PCI is anticipated.
  • Staged PCI is planned within 90 days following device removal.
  • Cardiogenic shock (SBP <90 mmHg for >1 hour with either cool clammy skin OR oliguria OR altered sensorium AND cardiac index <2.2 L/min/m2)
  • History of aortic valve replacement or repair
  • Documented presence of aortic stenosis (orifice area of 1.5cm2 or less)
  • Severe peripheral vascular disease that will preclude the use of a 14F access sheath, which is required for the insertion of the HeartMate PHP catheter
  • Known abnormalities of the aorta that would preclude surgery, including aneurysms and significant tortuosity or calcifications
  • Subject is on hemodialysis.
  • Liver dysfunction with elevation of liver enzymes and bilirubin levels to ≥ 3X ULN or Internationalized Normalized Ratio (INR) ≥2 or lactate dehydrogenase (LDH) > 2.5X ULN
  • Uncorrectable abnormal coagulation parameters (platelet count ≤75000/mm3 or INR ≥2.0 or fibrinogen ≤1.5 g/l)
  • Active systemic infection requiring treatment with antibiotics
  • Stroke or transient ischemic attack (TIA) within 6 months of procedure
  • Any allergy or intolerance to ionic and nonionic contrast media, anticoagulants, or antiplatelet therapy drugs that cannot be adequately premedicated
  • Subject is pregnant (For a female subject of childbearing potential, a pregnancy test must be performed within 14 days (≤14 days) prior to the index procedure per site standard test).
  • Participation in another clinical study of an investigational drug or device that has not met its primary endpoint
  • Presence of other anatomic or comorbid conditions, or other medical, social, or psychological conditions that, in the investigator's opinion, could limit the subject's ability to participate in the clinical investigation or to comply with followup requirements, or impact the scientific soundness of the clinical investigation results

Imaging Exclusion Criteria:

  • Mural thrombus in the left ventricle
  • Moderate to severe aortic insufficiency by echocardiographic assessment

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02468778


Contacts
Layout table for location contacts
Contact: Stacy Scribner 651-756-5602 Stacy.Scribner@Abbott.com
Contact: Mariah Tackett 206-276-1839 mariah.tackett@abbott.com

  Show 62 Study Locations
Sponsors and Collaborators
Abbott Medical Devices
Investigators
Layout table for investigator information
Study Director: Mariah Tackett Abbott

Layout table for additonal information
Responsible Party: Abbott Medical Devices
ClinicalTrials.gov Identifier: NCT02468778     History of Changes
Other Study ID Numbers: HeartMate PHP™ SHIELD II
First Posted: June 11, 2015    Key Record Dates
Last Update Posted: June 19, 2019
Last Verified: June 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: Yes
Pediatric Postmarket Surveillance of a Device Product: No
Keywords provided by Abbott Medical Devices:
HeartMate PHP
High Risk PCI
Mechanical circulatory support device
MCS
Abbott
Additional relevant MeSH terms:
Layout table for MeSH terms
Coronary Artery Disease
Coronary Disease
Myocardial Ischemia
Heart Diseases
Cardiovascular Diseases
Arteriosclerosis
Arterial Occlusive Diseases
Vascular Diseases